{"id":"https://openalex.org/W2655050774","doi":"https://doi.org/10.1007/s11060-017-2528-3","title":"Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab","display_name":"Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab","alternate_titles":[],"publication_year":2017,"publication_date":"2017-06-19","ids":{"openalex":"https://openalex.org/W2655050774","doi":"https://doi.org/10.1007/s11060-017-2528-3","mag":"2655050774","pmid":"https://pubmed.ncbi.nlm.nih.gov/28631191"},"language":"en","primary_location":{"id":"doi:10.1007/s11060-017-2528-3","doi":"https://doi.org/10.1007/s11060-017-2528-3","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s11060-017-2528-3","pdf_url":null,"source":{"id":"https://openalex.org/S175922936","display_name":"Journal of Neuro-Oncology","issn_l":"0167-594X","issn":["0167-594X","1573-7373"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Neuro-Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2655050774"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113917859","display_name":"Victor A. Levin","orcid":"https://orcid.org/0000-0003-3909-2101","observed_orcids":["https://orcid.org/0000-0003-3909-2101"]},"institutions":[{"id":"https://openalex.org/I1343052199","display_name":"Kaiser Permanente","ror":"https://ror.org/00t60zh31","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I1343052199"]},{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I4210119922","display_name":"Kaiser Permanente Redwood City Medical Center","ror":"https://ror.org/02bz7vk34","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343052199","https://openalex.org/I4210119922"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Victor A. Levin","raw_affiliation_strings":["Department of Neurosurgery and Neurosciences, Kaiser Permanente, Redwood City, CA, USA. vlevin11@gmail.com","The Universiy of Texas M.D. Anderson Cancer Center, Houston, TX, USA. vlevin11@gmail.com","Department of Neurosurgery and Neurosciences, Kaiser Permanente, Redwood City, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurosurgery and Neurosciences, Kaiser Permanente, Redwood City, CA, USA. vlevin11@gmail.com","institution_ids":["https://openalex.org/I1343052199","https://openalex.org/I4210119922"]},{"raw_affiliation_string":"The Universiy of Texas M.D. Anderson Cancer Center, Houston, TX, USA. vlevin11@gmail.com","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Department of Neurosurgery and Neurosciences, Kaiser Permanente, Redwood City, CA, USA","institution_ids":["https://openalex.org/I1343052199","https://openalex.org/I4210119922"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113692626","display_name":"James Chan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343052199","display_name":"Kaiser Permanente","ror":"https://ror.org/00t60zh31","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I1343052199"]},{"id":"https://openalex.org/I2801936213","display_name":"Kaiser Permanente Oakland Medical Center","ror":"https://ror.org/05rfek682","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343052199","https://openalex.org/I2801936213"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"James Chan","raw_affiliation_strings":["Pharmacy Outcomes Research Group, Kaiser Permanente, Oakland, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacy Outcomes Research Group, Kaiser Permanente, Oakland, CA, USA","institution_ids":["https://openalex.org/I1343052199","https://openalex.org/I2801936213"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015735736","display_name":"Meenal Datta","orcid":"https://orcid.org/0000-0001-5727-8992","observed_orcids":["https://orcid.org/0000-0001-5727-8992"]},"institutions":[{"id":"https://openalex.org/I121934306","display_name":"Tufts University","ror":"https://ror.org/05wvpxv85","country_code":"US","type":"education","lineage":["https://openalex.org/I121934306"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Meenal Datta","raw_affiliation_strings":["Department of Chemical and Biological Engineering, Tufts University, Medford, MA, 02155, USA","Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Chemical and Biological Engineering, Tufts University, Medford, MA, 02155, USA","institution_ids":["https://openalex.org/I121934306"]},{"raw_affiliation_string":"Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011524816","display_name":"Jennie L. Yee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343052199","display_name":"Kaiser Permanente","ror":"https://ror.org/00t60zh31","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I1343052199"]},{"id":"https://openalex.org/I2801936213","display_name":"Kaiser Permanente Oakland Medical Center","ror":"https://ror.org/05rfek682","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343052199","https://openalex.org/I2801936213"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jennie L. Yee","raw_affiliation_strings":["Clinic Administered Medications Drug Use Management, Kaiser Permanente, Oakland, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinic Administered Medications Drug Use Management, Kaiser Permanente, Oakland, CA, USA","institution_ids":["https://openalex.org/I1343052199","https://openalex.org/I2801936213"]}]},{"author_position":"last","author":{"id":null,"display_name":"Rakesh K. Jain","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Rakesh K. Jain","raw_affiliation_strings":["Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210087915"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5113917859"],"corresponding_institution_ids":["https://openalex.org/I1343052199","https://openalex.org/I1343551460","https://openalex.org/I4210119922"],"apc_list":{"value":4590,"currency":"USD","value_usd":4590},"apc_paid":null,"fwci":2.8831,"has_fulltext":false,"cited_by_count":53,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.92744855,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"134","issue":"2","first_page":"325","last_page":"330"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/renin-angiotensin-system-inhibitors","display_name":"renin-angiotensin system inhibitors","score":0.9980000257492065},{"id":"https://openalex.org/keywords/glioma","display_name":"glioma","score":0.8650000095367432},{"id":"https://openalex.org/keywords/glioblastoma","display_name":"glioblastoma","score":0.878000020980835},{"id":"https://openalex.org/keywords/recurrent-glioblastoma","display_name":"recurrent glioblastoma","score":0.9599999785423279},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8240000009536743},{"id":"https://openalex.org/keywords/low-dose-bevacizumab","display_name":"low-dose bevacizumab","score":0.8859999775886536},{"id":"https://openalex.org/keywords/conventional-chemotherapy","display_name":"cytotoxic chemotherapy","score":0.8130000233650208},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5550000071525574}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8856581449508667},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8525471091270447},{"id":"https://openalex.org/C2778227246","wikidata":"https://www.wikidata.org/wiki/Q1365309","display_name":"Glioma","level":2,"score":0.734812319278717},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.6660763025283813},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6433892250061035},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.5607720613479614},{"id":"https://openalex.org/C2776194525","wikidata":"https://www.wikidata.org/wiki/Q282142","display_name":"Glioblastoma","level":2,"score":0.5571467876434326},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5361300706863403},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5307607054710388},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4732925295829773},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.43339404463768005},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3262605369091034},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.10487401485443115},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.09350445866584778}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001932","descriptor_name":"Brain Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001932","descriptor_name":"Brain Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D001932","descriptor_name":"Brain Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005910","descriptor_name":"Glioma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005910","descriptor_name":"Glioma","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D005910","descriptor_name":"Glioma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D012042","descriptor_name":"Registries","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016016","descriptor_name":"Proportional Hazards Models","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057911","descriptor_name":"Angiotensin Receptor Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D060787","descriptor_name":"Neoplasm Grading","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/s11060-017-2528-3","doi":"https://doi.org/10.1007/s11060-017-2528-3","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s11060-017-2528-3","pdf_url":null,"source":{"id":"https://openalex.org/S175922936","display_name":"Journal of Neuro-Oncology","issn_l":"0167-594X","issn":["0167-594X","1573-7373"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Neuro-Oncology","raw_type":"journal-article"},{"id":"pmid:28631191","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28631191","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of neuro-oncology","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[{"id":"https://openalex.org/G4181830989","display_name":"TARGETING THE GRANULOMA MICROENVIRONMENT TO IMPROVE TUBERCULOSIS TREATMENT","funder_award_id":"F31HL126449","funder_id":"https://openalex.org/F4320337338","funder_display_name":"National Heart, Lung, and Blood Institute"},{"id":"https://openalex.org/G5672886551","display_name":"Integrative Pathophysiology of Solid Tumors","funder_award_id":"P01CA080124","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320308849","display_name":"Kaiser Permanente","ror":"https://ror.org/00t60zh31"},{"id":"https://openalex.org/F4320317998","display_name":"Orbus Therapeutics","ror":"https://ror.org/039hdbz42"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337338","display_name":"National Heart, Lung, and Blood Institute","ror":"https://ror.org/012pb6c26"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W1603491949","https://openalex.org/W1642622033","https://openalex.org/W1964128680","https://openalex.org/W1973313549","https://openalex.org/W1980758201","https://openalex.org/W2013247986","https://openalex.org/W2022540958","https://openalex.org/W2025106701","https://openalex.org/W2080202443","https://openalex.org/W2094546405","https://openalex.org/W2094825563","https://openalex.org/W2096287682","https://openalex.org/W2098054841","https://openalex.org/W2111092101","https://openalex.org/W2135783949","https://openalex.org/W2145221672","https://openalex.org/W2146628652","https://openalex.org/W2156901310","https://openalex.org/W2163342290","https://openalex.org/W2234225459","https://openalex.org/W2509882972","https://openalex.org/W2519556065","https://openalex.org/W2561590439","https://openalex.org/W2598367490"],"related_works":["https://openalex.org/W6902273724","https://openalex.org/W7203733555","https://openalex.org/W1642622033","https://openalex.org/W2092588545","https://openalex.org/W1976202809","https://openalex.org/W2569247365","https://openalex.org/W2013247986","https://openalex.org/W2795145026","https://openalex.org/W2806248992","https://openalex.org/W3004632817"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2655050774","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":9},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2017-06-30T00:00:00"}
